Alexion Pharma (ALXN) Offering Possible 40.85% Return Over the Next 10 Calendar Days

Alexion Pharma's most recent trend suggests a bearish bias. One trading opportunity on Alexion Pharma is a Bear Call Spread using a strike $99.00 short call and a strike $104.00 long call offers a potential 40.85% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $99.00 by expiration. The full premium credit of $1.45 would be kept by the premium seller. The risk of $3.55 would be incurred if the stock rose above the $104.00 long call strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Alexion Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Alexion Pharma is bearish.

The RSI indicator is at 25.06 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Alexion Pharma

3 Healthcare Stocks to Watch for the Long Run
Thu, 03 Oct 2019 14:11:09 +0000
It’s no secret that healthcare stocks have been under pressure due to geopolitical uncertainty, increased government regulation, and ongoing pressure on drug companies to lower prices. Take a look at the Biotechnology ETF (IBB) and see how badly the sector is underperforming.However, the greatest investment advice of all time comes from the Oracle of Omaha, Warren Buffett. He advised investors to be greedy when others are fearful and to be fearful when others are greedy. In short, Buffett believes the best way to make money on Wall Street is to look for quality companies that have fallen on hard times.Indeed, there are several “strong buy” stocks in the sector, which are set for significant gains in the coming months — at least, according to Wall Street analysts. We turned to TipRanks’ Stock Screener to see which healthcare stocks these analysts believe have plenty of upside potential ahead. That’s according to the upside potential from the average analyst price target. Let’s see how that works out now: Is HCA Healthcare Stock Setting Up for a Large Move Higher?Ranked No. 67 in the 2019 Fortune 500 list as the largest United States corporations by total revenue, HCA Healthcare (HCA) manages approximately 2,000 care sites, including 184 hospitals, urgent care centers, and physician clinics, 119 freestanding surgery centers, and ER’s in the United States and United Kingdom.  This September, HCA opened a new $10 million-dollar medical facility in Orlando, Florida; its third freestanding ER launch this year, bringing the company's net worth value to $43.24 billion. In addition, HCA has started construction in partnership with the University of Central Florida on a $175 million teaching hospital, The UCF Lake Nona Medical Center, set to open in fall 2020. 5-star Wolfe analyst Justin Lake believes that a "combination of significantly lower expectations and valuation leaves an increasingly interesting risk/reward." Despite near-term uncertainty about "general lack of visibility on mix/acuity and tough comps," the analyst sees "potential that 2Q results were simply white noise, similar to UHS 1Q19, which coupled w/modest cost cuts and extra biz day in qtr. leaves potential for 3Q rebound." Lake rates HCA a Buy with $141 price target, which implies about 22% upside from current levels. (To watch Lake's track record, click here)Lake is not the only fan of the healthcare provider on Wall Street, as TipRanks analytics exhibit HCA as a Strong Buy. Based on six analysts polled by in the last three months, five rate HCA a Buy, while only one rates the stock a Hold. The 12-month average price target stands at $157.17, marking a 37% upside from where the stock is currently trading. (See HCA's price targets and analyst ratings on TipRanks) Zoetis Stock Still Has Gasoline Left in the TankWith over 65 years of experience in animal health, Zoetis (ZTS) is what many believe to be the “go-to” developer and manufacturer of medicines, vaccines, biodevices, and diagnostic products for pets and livestock. The company sells its products in more than 100 countries worldwide and now boasts over 10,000 employees; virtually dominating the global animal health market. Zoetis stock has been knocking it out of the ballpark so far this year, rising by a whopping 43%, and Wall Street analysts say there’s still some gas left in the tank.5-star Stifel analyst Jonathan Block mentioned that the company's Q2 Animal Health survey showed how well ZTS’s product pipeline is doing, having him predict an upside on the company’s 2019-2022 revenue and ESP estimates. “The Triple”, feline pain, canine pain, and feline atopic dermatitis accounted for the vast majority of pharmaceutical product innovations that Veterinarians want, all of which Zoetis could or should bring into the market over the next 1-2+ years,” Block went on to say. Block rates ZTS a 'buy' with $140 price target, which implies about 14% upside from current levels. (To watch Block's track record, click here)TipRanks reveals the veterinary drug and vaccine maker as one drawing bullish attention on Wall Street. Out of 10 analysts polled in the last 3 months, 8 rate a Buy on AMD stock, 2 maintain a Hold. The 12-month average price target stands at $137.33, marking a nearly 12% upside potential from where the stock is currently trading.(See ZTS's price targets and analyst ratings on TipRanks)Is Alexion Stock Set to Jump Over 60%?Alexion (ALXN) is a global biopharmaceutical company focusing on treatment for rare diseases through the discovery and development of advanced medical therapies. The company is best known for its development of $3 billion-a-year bestseller Soliris, a drug used to treat the rare disorders ‘atypical Hemolytic Uremic Syndrome’ (aHUS) and ‘Paroxysmal Nocturnal Hemoglobinuria’. Due to the high cost of Soliris and its niche nature, the company continues to reign undefeated in the rare diseases sector and sees high-profit margins year-over-year. In addition, Alexion recently announced that it is replacing its CFO Paul Clancy with Aradhana Sarin, M.D., the company’s chief strategy and business officer. Sarin is responsible for $2 billion in recent pipeline acquisitions and has a strong M&A background. This shift into new leadership has analysts a little excited, one would say. 5-star RBC Capital analyst Kennen MacKay reiterated an Outperform rating (i.e. Buy) on ALXN stock, stating that he sees “Dr. Sarin as a strong successor given her prior position as Senior Vice President in Business and Corporate Strategy.” Adding that Sarin “has led ALXN's business development efforts including what view as an impressive string of acquisitions and partnerships.” All in all, Alexion stock has one of the best ratings by the Street. TipRanks reveals that ALXN has a Strong Buy analyst consensus rating with 12 'buy' ratings and only one 'hold' rating in the last three months. Meanwhile the average analyst price target of $163.30 suggests the stock has upside potential of nearly 66% from the current share price for the next 12 months. (See ALXN's price targets and analyst ratings on TipRanks)

Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?
Wed, 02 Oct 2019 14:10:02 +0000
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors flee Biotech ETFs as they Lag Bull Market
Mon, 30 Sep 2019 18:52:13 +0000
While the S&P 500 is up nearly 19% heading into the final quarter of the year, biotech stocks are badly lagging the market, punishing the performance of many ETFs and other funds holding shares of companies such as Biogen (BIIB), Regeneron Pharmaceuticals Inc. (REGN), BioMarin Pharmaceutical Inc. (BMRN), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Inc. (VRTX), and Alexion Pharmaceuticals Inc. (ALXN). The increasingly bearish sentiment is reflected in six consecutive weeks of outflows from biotech funds, amounting to about $2.1 billion, and marking the longest stretch of continuous outflows in nearly two years, as outlined by Barron’s. Weakness in the biotech sector has caused a long list of ETFs to fall sharply from their highs in the last few months, including the giant iShares Nasdaq Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and Invesco Dynamic Biotechnology & Genome ETF (PBE), just to name a few.

Investors Who Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Shares Five Years Ago Are Now Down 45%
Mon, 30 Sep 2019 10:24:08 +0000
The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with…

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN
Thu, 26 Sep 2019 15:32:03 +0000
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.